Cargando…
A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation
BACKGROUND: We conducted a placebo-controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. METHODS: We compared azithromycin (250 mg alternate days, 12 weeks) with placebo. Primary outcome was FEV(1) change at 12 weeks. RESULTS: 48 patients were...
Autores principales: | Corris, Paul A, Ryan, Victoria A, Small, Therese, Lordan, James, Fisher, Andrew J, Meachery, Gerard, Johnson, Gail, Ward, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413845/ https://www.ncbi.nlm.nih.gov/pubmed/25714615 http://dx.doi.org/10.1136/thoraxjnl-2014-205998 |
Ejemplares similares
-
Long-term effect of azithromycin in bronchiolitis obliterans syndrome
por: Gan, C.Tji-Joong, et al.
Publicado: (2019) -
Lung transplantation for interstitial lung disease: evolution over three decades
por: Leong, Swee W, et al.
Publicado: (2023) -
Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation
por: Müller, Catharina, et al.
Publicado: (2017) -
Bronchial epithelial cells cultured from clinically stable lung allograft patients promote the development of macrophages from monocytes rather than dendritic cells
por: Ward, C, et al.
Publicado: (2009) -
Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis
por: Santos, Jesse, et al.
Publicado: (2023)